10 participants
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-14
- Start Date:
- 2024-08-07
- Completion:
- 2026-10-01
Conditions
- Metastatic Renal Cell Carcinoma
Interventions
- DRUG
No Results Yet